Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

$19.45 -0.05 (-0.26%)

(As of 12/20/2024 05:15 PM ET)

Arrowhead Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
4

Buy
7

Based on 11 Wall Street analysts who have issued ratings for Arrowhead Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 4 have given a hold rating, and 7 have given a buy rating for ARWR.

Consensus Price Target

$42.70
119.54% Upside

According to the 11 analysts' twelve-month price targets for Arrowhead Pharmaceuticals, the average price target is $42.70. The highest price target for ARWR is $80.00, while the lowest price target for ARWR is $24.00. The average price target represents a forecasted upside of 119.54% from the current price of $19.45.

Get the Latest News and Ratings for ARWR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arrowhead Pharmaceuticals and its competitors.

ARWR Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	10 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$42.70	$45.33	$44.25	$51.15
Forecasted Upside	119.54% Upside	144.52% Upside	121.25% Upside	68.55% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

ARWR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARWR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arrowhead Pharmaceuticals Stock vs. The Competition

Type	Arrowhead Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.64	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	119.54% Upside	25,828.59% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent ARWR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/20/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00	+298.80%
12/12/2024	Chardan Capital 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00	+163.97%
11/29/2024	Sanford C. Bernstein 3 of 5 stars		Lower Target	Market Perform ➝ Market Perform	$27.00 ➝ $24.00	-8.22%
11/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$62.00 ➝ $45.00	+90.52%
11/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$27.00 ➝ $26.00	+7.08%
9/26/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$42.00 ➝ $42.00	+110.00%
This is the worst sign for the U.S. stock market in 50 years (Ad) The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" Click here to see Dan's new, urgent warning about the U.S. market for 2025.
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
8/12/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00	+139.65%
6/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$31.00	+22.58%
5/13/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$36.00 ➝ $27.00	+23.74%
1/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$29.00 ➝ $37.00	+17.61%
7/21/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
5/12/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/12/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$40.00	-0.20%
5/3/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$80.00	+138.24%
2/7/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$60.00 ➝ $58.00	+73.08%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:14 PM ET.

ARWR Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Arrowhead Pharmaceuticals is $42.70, with a high forecast of $80.00 and a low forecast of $24.00.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARWR shares.
: According to analysts, Arrowhead Pharmaceuticals's stock has a predicted upside of 119.54% based on their 12-month stock forecasts.
: Arrowhead Pharmaceuticals has been rated by research analysts at Chardan Capital, Citigroup, HC Wainwright, Piper Sandler, Royal Bank of Canada, and Sanford C. Bernstein in the past 90 days.
: Analysts like Arrowhead Pharmaceuticals less than other "medical" companies. The consensus rating score for Arrowhead Pharmaceuticals is 2.64 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ARWR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This is the worst sign for the U.S. stock market in 50 years (Ad)

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

This page (NASDAQ:ARWR) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target